Get the Stockscreener App
0.00
100.00%
-84.95
After Hours:
84.97
84.97
+
Crinetics Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
See More
Previous Close:
$84.95
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$8.99B
Revenue:
$18.07M
Net Income/Loss:
$-496.39M
P/E Ratio:
0.00
EPS:
-5.1333
Net Cash Flow:
$-419.52M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$85.01
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
0.00 | 8.99B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis - Yahoo Finance
Crinetics Pharmaceuticals, Inc. SEC Filing (Sep 11, 2026) - Stock Titan
Vertex Pharma stock falls as market digests Crinetics deal and valuation risks - ad-hoc-news.de
Vertex Pharma stock heads into the open after a 3.1 percent drop - ad-hoc-news.de
CRNXCrinetics Pharmaceuticals Inc Revenue Breakdown - Finviz
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send? - TradingKey
Vertex Shares Fall as Investors Digest Crinetics Acquisition and Related Financing Plans - Moomoo
Vertex shares fall as investors digest Crinetics acquisition and related financing plans - Quiver Quantitative
Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock - Stocktwits
Enterprise value to EBITDA forward of Crinetics Pharmaceuticals Inc – SWB:6Z4 - TradingView
Vertex sees over $5 billion peak sales from Crinetics assets - scanx.trade
Ademi LLP investigates Crinetics sale to Vertex over fair price - scanx.trade
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC - The National Law Review
Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Crinetics Pharmaceuticals, Inc.(NasdaqGS: CRNX) dropped from S&P Global BMI Index - marketscreener.com
Crinetics Pharmaceuticals, Inc.(NasdaqGS: CRNX) dropped from S&P TMI Index - marketscreener.com
CRNX Suspended by Cantor Fitzgerald -- Rating Maintained at Neut - GuruFocus
Crinetics Pharmaceuticals, Inc.(NasdaqGS: CRNX) dropped from Russell 2000 Growth Index - marketscreener.com
News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX - Moomoo
$85-per-share buyout shows how Crinetics (CRNX) insiders were paid in Vertex deal - Stock Titan
Vertex deal cashes out Crinetics (NASDAQ: CRNX) director’s stock and options - Stock Titan
Crinetics (NASDAQ: CRNX) director’s stock and options converted to $85 cash in Vertex deal - Stock Titan
Vertex deal cancels Crinetics (NASDAQ: CRNX) director's shares and options - Stock Titan
Vertex buyout pays Crinetics (CRNX) insider in cash, but his options fared very differently - Stock Titan
Vertex buyout pays Crinetics (NASDAQ: CRNX) director for stock and options - Stock Titan
Crinetics (NASDAQ: CRNX) director’s stock, options and RSUs all vest and turn to cash in Vertex buyout - Stock Titan
Crinetics (NASDAQ: CRNX) CCO awards vest, then are cashed out or wiped in $85-a-share Vertex merger - Stock Titan
Takeover hands Crinetics (CRNX) science chief an $85-a-share cash exit - Stock Titan
Vertex’s $85 deal cashes out Crinetics (NASDAQ: CRNX) awards - Stock Titan
Crinetics (CRNX) shareholders receive $85 per share as Vertex takeover closes - Stock Titan
Crinetics Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform - Yahoo Finance
Vertex Pharmaceuticals Completes $10 Billion Acquisition of Crinetics Pharmaceuticals at $85 Per Share - Kalkine Media
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes - marketscreener.com
Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition - marketscreener.com
Nasdaq starts delisting Crinetics (NASDAQ: CRNX) shares and ends its Section 12(b) listing - Stock Titan
Crinetics Pharmaceuticals Ends ATM Sales Agreement With SVB Leerink, Cantor Following Vertex Merger - TradingView
Crinetics Pharmaceuticals (NASDAQ: CRNX) exits in $10B Vertex deal and what shareholders are getting - Stock Titan
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team - Business Wire
Crinetics Pharmaceuticals, Inc.(NasdaqGS: CRNX) dropped from NASDAQ Composite Index - marketscreener.com
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Eastern Progress
Shareholder approval clears way for Crinetics (NASDAQ: CRNX) sale to Vertex - Stock Titan
Crinetics Pharmaceuticals held special shareholder meeting on merger proposal vote - Bitget
Crinetics Pharmaceuticals stock hits all-time high at 84.8 USD By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals stock hits all-time high at 84.8 USD - investing.com
The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP - Yahoo Finance
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume IncreaseWhat's Next? - MarketBeat
TD Cowen and Evercore ISI downgrade Crinetics Pharmaceuticals - scanx.trade
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth - TradingView
Crinetics (CRNX) Trading: Stays Close to Unchanged at $84.69 in the Latest Reading; Price Levels - Vinanet
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):